Back to Resource Center

Investment in post-efficacy R&D critical for PrEP, other new HIV prevention options

July 2015

Click for full info +

Investment in post-efficacy R&D critical for PrEP, other new HIV prevention options

Investment in post-efficacy R&D critical for PrEP, other new HIV prevention options
17 July 2015
In this Press Release:
Health Risk(s):

  • HIV
  • Product Type(s):

  • Microbicides
  • MPTs
  • Vaccines
  • Topic(s):

  • Advocacy
  • Funding

  • Full Info:


    Resource Type:

    Press Release

    Back to Resource Center